Clinical trials: Urinary
Pelvic Organ Prolapse (POP)
Operations and Pelvic Muscle Training in the Management of Apical Support Loss: The OPTIMAL Trial
Pelvic organ prolapse is common among women with a prevalence that has been estimated to be as high as 30%. Pelvic organ prolapse often involves a combination of support defects involving the anterior, posterior and/or apical…
- Trial name
- OPTIMAL (NCT00597935)
- Testing
- SSLF, ULS, PMT
- Where
- 9 sites in United States
- Volunteers
- 374 people
- Sponsor
- NICHD Pelvic Floor Disorders Network
Bladder Cancer
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
The purpose of this study is to determine whether Patients with Locally Advanced or Metastatic Bladder Cancer who receive Eribulin Mesylate Administered in Combination with Gemcitabine Plus Cisplatin Versus Gemcitabine Plus…
- Trial name
- NCT01126749
- Testing
- Gemcitabine, E7389, Cisplatin
- Where
- 42 sites in United States, Germany and 4 more
- Volunteers
- 92 people
- Sponsor
- Eisai Inc.
Urinary Incontinence, Stress
Autologous Cell Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery
To study the safety and potential efficacy of Autologous Muscle Derived Cells for Urinary Sphincter Repair (AMDC-USR) for the treatment of male stress urinary incontinence (SUI) for patients that have undergone prior prostate…
- Conditions
- Urinary Incontinence, Stress, Urination Disorders, Urologic Diseases
- Trial name
- NCT02291432
- Testing
- autologous muscle-derived cells (AMDC)
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Cook MyoSite
Overactive Bladder
Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder
This study will help determine if behavior modification performed in conjunction with oral Vesicare anticholinergic therapy is more effective for treating overactive bladder symptoms than oral Vesicare anticholinergic therapy…
- Trial name
- NCT00821184
- Testing
- Vesicare (solifenacin), Vesicare (solifenacin) plus behavioral modification
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Lahey Clinic
Bladder Cancer
FITBIT Study on Mobility and Readmissions After Radical Cystectomy
This is a two-arm randomized, controlled trial during the postoperative period after major abdominal surgery for cancer, including for example radical cystectomy, nephrectomy, colectomy, comparing a control group that uses a…
- Trial name
- FITBIT (NCT04314778)
- Testing
- social incentive-based gamification
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- University of Pennsylvania
Urinary Incontinence, Overactive Bladder
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1
The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® (AbobotulinumtoxinA) doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult…
- Trial name
- CONTENT1 (NCT02660138)
- Testing
- Botulinum toxin type A
- Where
- 81 sites in United States, Canada and 8 more
- Volunteers
- 227 people
- Sponsor
- Ipsen
Bladder Carcinoma
TracelT Hydrogel in Localizing Bladder Tumors in Patients Undergoing Radiation Therapy for Bladder Cancer
This pilot clinical trial studies how well TracelT hydrogel works in localizing bladder tumors in patients undergoing radiation therapy for bladder cancer.
- Trial name
- NCT03125226
- Testing
- Polyethylene Glycol Hydrogel
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Washington
Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8
Behavioral Dietary Intervention for the Improvement of Bladder Cancer Survivorship
This phase I trial investigates how well a healthy eating program works in improving outcomes in patients with bladder cancer. The behavioral dietary program consists of educational materials, live phone calls, and interactive…
- Conditions
- Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
- Trial name
- NCT04548193
- Testing
- Behavioral Dietary Intervention, Educational Intervention, Questionnaire Administration
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Roswell Park Cancer Institute
Overactive Bladder
Procedural Discomfort Related to Number of Intradetrusor Botox Injections
Injection of intradetrusor OnabotulinumtoxinA (BTX-A) is a highly efficacious therapy with a reliable safety profile and demonstrable improvements in subjective and objective measures for overactive bladder (OAB) symptom control.
- Trial name
- BIND (NCT05652036)
- Testing
- Intradetrusor Botox Injections
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- The Methodist Hospital Research Institute
Bladder Cancer
Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy
The purpose of this study is to evaluate whether adding pembrolizumab (Keytruda) to the combination of gemcitabine and cisplatin will improve shrinkage of the tumor before having a cystectomy, for people with muscle-invasive…
- Trial name
- NCT02690558
- Testing
- pembrolizumab, gemcitabine and cisplatin
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Pressure Ulcers Stage III, Pressure Ulcer, Stage IV
Comparing Concomitant Use of ACell MicroMatrix® and ACell Cytal™ to Standard of Care in Stage 3 or 4 Pressure Injuries
The purpose of this study is to evaluate incidence of complete epithelialization in stage 3 \& 4 pressure ulcers using ACell products.
- Conditions
- Pressure Ulcers Stage III, Pressure Ulcer, Stage IV, Pressure Ulcer
- Trial name
- NCT03283787
- Testing
- MicroMatrix® and Cytal™ Wound Matrix 2-Layer, MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT, Negative Pressure Wound Therapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Integra LifeSciences Corporation
Urinary Tract Diseases
Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures
A prospective, randomized controlled study to determine the efficacy of liposomal bupivacaine given by local injection at all the wound sites in patients undergoing urologic surgeries.
- Trial name
- NCT02805504
- Testing
- Exparel, Marcaine
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Loma Linda University
Interstitial Cystitis
Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis
The purpose of this study is to evaluate the safety and effectiveness of pentosan polysulfate sodium 100 mg once a day, pentosan polysulfate sodium 100 mg three times a day, and placebo for 24 weeks for the relief of bladder pain…
- Trial name
- NCT00086684
- Testing
- Pentosan polysulfate sodium 100 mg
- Where
- 65 sites in United States, Canada
- Volunteers
- 369 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Vaginal Prolapse
Observational Data Collection of Surgical Outcomes in the Treatment of Vaginal Prolapse With AMS Products
This registry was observational (only collected information typically noted by the surgeon when their patients were routinely seen); there was no change to the care the patient received as a result of being part of the registry).
- Trial name
- POWER1012 (NCT00388947)
- Testing
- AMS Prolapse Product
- Where
- United States
- Volunteers
- 1,543 people
- Sponsor
- ASTORA Women's Health
Urge Incontinence, Overactive Bladder (OAB)
A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
The purpose of this study was to evaluate the efficacy of mirabegron for the treatment of overactive bladder (OAB) in Chinese participants.
- Trial name
- NCT04562090
- Testing
- mirabegron
- Where
- 15 sites in China
- Volunteers
- 249 people
- Sponsor
- Astellas Pharma China, Inc.
Urinary Incontinence
Mobile App-treatment of Mixed and Urgency Urinary Incontinence in Women
The purpose of this study is to determine whether a comprehensive treatment programme for self-management of mixed and urgency urinary incontinence via a mobile app is effective.
- Trial name
- NCT03097549
- Testing
- Tät®II Information app, Tät®II Treatment app
- Where
- Sweden
- Volunteers
- 142 people
- Sponsor
- Umeå University
Female Stress Urinary Incontinence
Treatment of Stress Urinary Incontinence Via Smartphone
The purpose of this study is to determine whether treatment of stress urinary incontinence (SUI) via smartphone is effective.
- Trial name
- NCT01848938
- Testing
- Smartphone treatment with PFMT
- Where
- Sweden
- Volunteers
- 123 people
- Sponsor
- Umeå University
Lymphoma, Digestive System Diseases
Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
Incidence of cancer in 75+ years old is 16,500 new cases per year, more than fifty percent of people with cancerThey are very few therapeutic trials dedicated.
- Conditions
- Lymphoma, Digestive System Diseases, Ovarian Diseases, Pulmonary Disease
- Trial name
- PHRC2003 (NCT00210249)
- Where
- 18 sites in France
- Volunteers
- 364 people
- Sponsor
- Institut Bergonié
Hypercholesterolemia
A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)
The purpose of this study is to evaluate the potential effects of ER niacin/laropiprant, ER niacin, laropiprant, and placebo over the course of seven days on urinary levels of a metabolite of thromboxane A2 (TxA2), as a marker of…
- Trial name
- NCT00769132
- Testing
- Comparator: niacin + laropiprant, Comparator: niacin, Comparator: laropiprant
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Retention, Urinary
Investigation of Non-CE Marked Intermittent Catheters for Females
Investigation of novel non-CE marked intermittent catheters. The study was a randomized, single blinded, cross-over investigation comparing two new catheters for females with a comparator catheter.
- Trial name
- NCT04557787
- Testing
- SpeediCath® Standard female, New intermittent Variant 1 catheter for females, New intermittent Variant 2 catheter for females
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Coloplast A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.